Drugs / IP-001
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06630624 | Jul 2024 → Aug 2029 expected | metastasis from malignant tumor of colon | M.R. Meijerink | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05688280 | Nov 2022 → Feb 2025 overdue | colon carcinoma, metastatic neoplasm, non-small cell lung carcinoma, soft tissue sarcoma | Immunophotonics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03993678 | Oct 2020 → Jul 2025 | cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06526338 | Jul 2024 → Dec 2029 expected | hepatocellular carcinoma | Robert C. Martin | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07321847 | May 2026 → Dec 2033 expected | metastasis from malignant tumor of colon, rectal cancer | Immunophotonics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | Immunophotonics, Inc. | Regulatory Immunophotonics Expands Global IP Portfolio with China Patent Grant immunophotonics.com ↗
Immunophotonics has strengthened its global intellectual property portfolio with the issuance of a patent by the China National Intellectual Property Administration (CNIPA). |
| 2023-05-18 | Immunophotonics, Inc. | Regulatory Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S. immunophotonics.com ↗
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of patients based on the company’s investigational new drug (IND) application. |
| 2023-04-05 | Immunophotonics, Inc. | Regulatory Indian Patent Office Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001 immunophotonics.com ↗
Immunophotonics is excited to announce that its composition-of-matter patent has been granted by the Indian Patent Office (ISA/IPEA). |
| 2023-01-11 | Immunophotonics, Inc. | Results Poster Presented at the ESMO Immuno-Oncology Congress immunophotonics.com ↗
A poster summarizing the results of the Phase 1b portion of the study SAKK 66/17 concerning the combination of thermal ablation with Immunophotonics’s lead asset, IP-001 TM , in patients with advanced solid tumors was presented at the ESMO Immuno-Oncology Congress on December 7-9, 2022, in Geneva, Switzerland. |
| 2022-11-08 | Immunophotonics, Inc. | Results Wei Chen’s Paper Publication in the Journal for ImmunoTherapy of Cancer (JITC) immunophotonics.com ↗
Check out this key publication on how ablation + IP-001 leads to activation of T cells and a de novo antitumor T-cell response. |
| 2022-02-04 | Immunophotonics, Inc. | Results Wei R. Chen B Cell Paper Publication immunophotonics.com ↗
Hot off the press: Another part of the mechanism of action of how IP-001 (GC) remodels the tumor microenvironment revealed! |
| 2021-02-25 | Immunophotonics, Inc. | Results Study Shows IP-001 to Amplify Tumoricidal and Immune Effect of Cancer Ablation Therapies immunophotonics.com ↗
A paper recently published in Cells has described how Immunophotonics’ immune-stimulating drug IP-001 was shown to be effective against metastatic tumors when combined with different forms tumor ablation. |
| 2019-06-21 | Immunophotonics, Inc. | Regulatory Immunophotonics Receives Swissmedic Approval to Commence Phase 1B/2A Clinical Trial in Switzerland immunophotonics.com ↗
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled “Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.” |
All press releases naming this drug 13 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03993678 ↗ |
| Modality | Other / unclassified | “IP-001 is a novel, non-cytotoxic, immunostimulatory glycan polymer” NCT07321847 ↗ |
| Route | Other | “IP-001 will be injected in and around the ablated lesion” NCT03993678 ↗ |